Antitrust M&A

Weil has an impressive track record of obtaining antitrust clearance in “bet-the-company” mergers, acquisitions and joint ventures.

Notable Representations, Key Contacts

Weil offers global solutions to our clients’ Antitrust/Competition transactional needs with one of the largest, most diversified and well-respected practices in the world. Trusted with many of the largest mergers in the last two decades, we bring to bear a combination of law firm and public-sector experience.

We coordinate multi-jurisdictional filings to assure maximum chances for swift approval and protect our clients against the adverse effects of mergers through effective advocacy before various governmental agencies.

We help clients structure transactions and business practices that minimize antitrust concerns. Collaborating with lawyers in practices including Mergers & Acquisitions, Intellectual Property, Restructuring and Corporate Governance, we provide integrated solutions to competition-related business issues.

Former Government Officials

Many of our partners are high-level government antitrust officials and formerly headed divisions at the Federal Trade Commission, responsible for review of mergers and acquisitions in numerous industries, including pharmaceutical, medical device, biotechnology, aerospace, defense, industrial, scientific, technology, retail, hospitals and consumer products.

This background provides the group with significant experience and insight into the merger review process and the substantive analysis that may be applied to transactions in these and other industries.

Shaping U.S. Antitrust Policy

Our team has been at the forefront of U.S. antitrust policy and procedure for many years, and while in important government positions assisted in developing the government’s approach to merger enforcement, influenced the body of Hart-Scott-Rodino rulings, and designed the government’s merger discovery process.

International Competition

Our Antitrust/Competition international network helps multinational companies meet the challenges of globalization, including increased scrutiny of mergers and acquisitions by regulatory agencies throughout the world. We have achieved significant success before major authorities and courts in the U.S., Europe, and many other jurisdictions.

With competition lawyers in the United States, European Union, and Eastern Europe, Weil has the international reach and experience to handle multinational reviews of mergers and acquisitions.

In countries where we do not have offices, we have developed strong and effective collaborative relationships with the best local competition law firms.

Selected Representations

Complex transactions across an array of industries

Abbott Laboratories

AbbVie

ALFA

Allergan

AK Steel

ExxonMobil

Health Management Associates

Iron Mountain

Johnson & Johnson

Kinder Morgan

Sanofi

Scripps Networks Interactive

Sherwin-Williams

Signet Jewelers Limited

Walgreens Boots Alliance

Weil represented Walgreens Boots Alliance (WBA) in its acquisition of almost 2,000 Rite Aid stores, a transaction valued at $4.377 billion. U.S. Federal Trade Commission clearance was secured following a two-year review that required a creative restructuring of the transaction in order to obtain clearance.
Weil represented WBA in a joint venture in which a newly formed company controlled by KKR, with WBA as a minority investor, acquired PharMerica Corporation, a leading provider of institutional pharmacy, specialty infusion and hospital pharmacy management services. The all-cash transaction was valued at approximately $1.4 billion. Clearance from the U.S. Federal Trade Commission was achieved without a Second Request being issued.
Weil represented Walgreens (n/k/a Walgreens Boots Alliance) in successfully securing antitrust clearance for its $23.8 billion acquisition of the 55% it did not already own of Alliance Boots GmbH (Switzerland), and in its previous purchase of a 45% interest in Alliance Boots, the largest acquisition in Walgreen’s company history.
Weil, in an earlier transaction, successfully represented Walgreens in connection with the company’s (and Alliance Boots’) acquisition of an equity position in AmerisourceBergen (one of the nation’s leading drug wholesalers), and the strategic, long-term alliance between the three companies. As part of this transaction, Walgreens entered into a 10-year comprehensive distribution agreement with AmerisourceBergen and provided AmerisourceBergen access to Walgreens and Alliance Boots’ joint venture to purchase generic and branded pharmaceuticals. This highly complex and innovative transaction was reviewed in multiple jurisdictions and raised a wide range of potential issues. As a result of our substantial industry expertise and effective advocacy, Weil was able to successfully coordinate the global antitrust process and obtain unconditional clearance for the transaction without a Second Request.
Also successfully represented Walgreens before the antitrust authorities in numerous other transactions, including the company's $1.1 billion acquisition of Duane Reade.

Willis Group Holdings

Key Contacts

Kevin J. Arquit

Partner

New York

+1 (212) 310-8950
kevin.arquit@weil.com

Steven A. Newborn

Partner

Washington, D.C.

+1 (202) 682-7005
steven.newborn@weil.com

See list of lawyers globally

Firm News & Announcements

Weil Shortlisted in Six Categories for LMG’s Life Sciences Awards 2018 Firm Announcement — August 06, 2018
Four Weil Partners Named Law360 Rising Stars in 2018 Firm Announcement — August 06, 2018
Weil Advised Genstar Capital and Boyd Corporation in Boyd’s Sale to Goldman Sachs Deal Brief — July 11, 2018
Weil Advises Genstar Capital in its $910M Sale of the Global Marine and Mobile Business of Power Products Holdings LLC to Brunswick Corporation Deal Brief — July 02, 2018
Weil Advises Gores Holdings II, Inc. in its $2.4B Transaction with Verra Mobility Deal Brief — June 21, 2018

View all

Weil’s Counsel to Allergan Wins “Merger Control Matter of the Year” for the Americas

Global Competition Review Awards 2017

Weil Named Antitrust Firm of the Year

Legal Media Group’s Life Sciences Awards 2016

Co-Head of the Antitrust/Competition practice Steven Newborn and Antitrust partners Steven Bernstein and Jeffrey Perry named “Trailblazers” by The National Law Journal in 2015, 2016 and 2017, respectively

“Merger Control Matter of the Year” for the Americas

Global Competition Review Awards 2017

Awards and Recognition, Speaking Engagements, Latest Thinking, Firm News & Announcements, Firm News & Announcements

Awards and Recognition

Weil’s Counsel to Allergan Wins “Merger Control Matter of the Year” for the Americas Award Brief — Global Competition Review Awards 2017
Weil Named a "Leading" Firm for Competition/Antitrust: USA Award Brief — Chambers Global 2018
Weil Ranked Tier 1 for Merger Control Award Brief — Legal 500 US 2018
Jeff White Named 2018 Rising Star for Antitrust/Competition by Law360 Award Brief — Law360 2018
Weil Shortlisted for “Antitrust Firm of the Year” Award Brief — Legal Media Group’s Sixth Annual Life Sciences Awards, 2018
Weil Named 2017 Competition Practice Group of the Year Award Brief — Law360 2017

View all

Speaking Engagements

Hot Topics Speaker(s): Kevin J. Arquit
April 12, 2018 — Washington, D.C — Weil Antitrust/Competition Co-Head Kevin Arquit spoke at the ABA’s 66th Antitrust Law Spring Meeting on a broad-ranging panel discussing the vital issues in antitrust and consumer protection policy, enforcement and litigation, and how events of the past year have set the stage for future trends.
Department of Justice Roundtable on Criminal Antitrust Compliance Speaker(s): Adam C. Hemlock
April 09, 2018 — Washington, DC — Department of Justice, Antitrust Division

View all